Physician profile
Pinkie Fitts
NPI 1407256217
$443,971.95
in general payments reported to CMS, 2019-2025
16 companies · $147K in 2025
The $147K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42K · 2022: $86K · 2023: $70K · 2024: $99K · 2025: $147K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $254K · Travel and Lodging: $40K · Consulting Fee: $16K · Food and Beverage: $5,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $254,184.50 |
| Travel and Lodging | $40,321.05 |
| Consulting Fee | $16,125.50 |
| Food and Beverage | $5,826.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $440,667.34 | 2021-2025 | Ingrezza |
| Abbvie INC. | $548.43 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $477.44 | 2021-2023 | Qelbree |
| Alkermes, INC. | $400.58 | 2021-2022 | |
| Bausch Health US, LLC | $318.91 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $304.45 | 2021-2022 | |
| Lundbeck LLC | $232.77 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $198.58 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $176.40 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $167.38 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $145.46 | 2021-2022 | |
| Eisai INC. | $131.88 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.63 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $54.92 | 2021 | |
| Adlon Therapeutics L.P. | $18.43 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $15.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pinkie Fitts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.